LightNews LightNews
sabian-eldritch.bsky.social
@sabian-eldritch.bsky.social
10 followers 28 following 5 posts
Posts Replies Media Videos
Reposted
burgerkrieg.bsky.social
www.youtube.com/watch?v=51Mu...
I promise you, you have not heard this LOST theory before
My LOST Theory that Makes Sense and Ties it All Together (90 Minutes)
YouTube video by TheBurgerkrieg
www.youtube.com
March 14, 2025 at 7:58 PM
sabian-eldritch.bsky.social
Customized my desktop with art of my late beloved.
January 19, 2025 at 8:42 AM
Reposted
hankgreen.bsky.social
I always said “this is the best year so far in human history to get cancer” and John retorted, “yeah, but next year would have been better.”

Truly ridiculous how right he was…
Two years after starting treatment, about 92% of trial participants randomly assigned to the nivolumab–AVD group were alive without their cancer starting to grow again—a measure known as progression-free survival—compared with 83% in the brentuximab–AVD group. People in the nivolumab–AVD group also had fewer side effects overall and fewer serious side effects, according to findings reported October 17 in the New England Journal of Medicine. The immunotherapy drug nivolumab (Opdivo) should be part of the initial treatment of teens and adults with advanced forms of classic Hodgkin lymphoma, according to updated results from a large NCI-funded clinical trial. In the nearly 1,000-patient trial, treatment with nivolumab and a three-drug chemotherapy regimen called AVD was better at eliminating cancer and keeping it at bay than the current standard initial treatment for the disease, AVD combined with the targeted therapy brentuximab (Adcetris).
January 13, 2025 at 4:00 AM